Join

Compare · HRMY vs LLY

HRMY vs LLY

Side-by-side comparison of Harmony Biosciences Holdings Inc. (HRMY) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both HRMY and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • LLY is the larger of the two at $1.04T, about 569.0x HRMY ($1.83B).
  • Over the past year, HRMY is down 10.5% and LLY is up 44.9% - LLY leads by 55.4 points.
  • LLY has been more active in the news (21 items in the past 4 weeks vs 12 for HRMY).
  • LLY has more recent analyst coverage (25 ratings vs 23 for HRMY).
PerformanceHRMY-10.48%LLY+44.92%
2025-06-02+0.00%2026-06-01
MetricHRMYLLY
Company
Harmony Biosciences Holdings Inc.
Eli Lilly and Company
Price
$31.82+0.66%
$1082.08-2.07%
Market cap
$1.83B
$1.04T
1M return
+1.74%
+15.75%
1Y return
-10.48%
+44.92%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2020
News (4w)
12
21
Recent ratings
23
25
HRMY

Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United States. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

LLY

Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Latest HRMY

Latest LLY